ROVI is a fully integrated Spanish specialty pharmaceutical company engaged in the research, development, in-licensing, manufacturing and marketing of small molecule and specialty biologic drugs.
The Company has a diversified portfolio of products that it markets in Spain through its specialized sales force, calling on specialist physicians, hospitals and pharmacies. ROVI’s portfolio of 30 principal marketed products is currently anchored by the internally-developed, second generation low molecular weight heparin, Bemiparin.
ROVI’s research and development pipeline is focused primarily on the expansion of applications, indications and alternative mechanisms of action for the heparin-derived products and other glycosaminoglycans and on the development of new controlled release mechanisms based on ISMTM technology, with the aim of obtaining new pharmaceutical products that enable the regular administration of formulations which are administered daily in chronic and prolonged treatments.
ROVI manufactures the active biological ingredient (Bemiparin) for its principal proprietary products and for injectable pharmaceutical products developed by its own in-house research team, and utilizes its state-of-the-art filling and packaging capabilities to provide a broad array of toll manufacturing services to leading international pharmaceutical companies, primarily in the area of pre-filled syringes. In addition, ROVI provides contract manufacturing and packaging services of solid oral pharmaceutical dosage forms, using the most enhanced technology, Roller Compaction.
Additional information about ROVI is available on the company’s website: www.rovi.es
LABORATORIOS FARMACÉUTICOS ROVI
| C/ Alfonso Gómez, 45 |
| 28037, Madrid |
| Tel: |
| Fax: (+34) 913 047 881 |
| e-mail: rovi@rovi.es |
Since PharmaBoardroom interviewed Juan López-Belmonte, CEO of Rovi, in 2008, the market has changed drastically. López-Belmonte outlines some of those changes and how Rovi has successfully adapted, having achieved significant…
A new study shows that the Spanish population is unclear on the meaning of self-care and often seeks a second opinion online post-visiting the doctor. Although 82.7% of Spaniards…
Andreu Mas-Colell, former minister of finance for Catalonia and president of the Barcelona Institute of Science and Technology (BIST), discusses the mission and activities of the institution as a driver…
According to a survey carried out by the Spanish Foundation for Science and Technology (FECYT) over half of the Spanish population believe Pseudo-therapies to be of real value. “Public…
Manuel Ramos Ortega, chairman of Labiana, a Spanish CDMO, highlights his strategy to create company stability and discusses the major trends in the manufacturing world of human medicines. Furthermore, he…
Xavier Carbonell, CEO of Palex Group, a leading Spanish medical device player, discusses how the company’s growth has been triggered by acquisitions to grow their portfolio and distribution arm, as…
After a recent course of political shifts, Spain now finds itself with a new minister of health; the third since this past June. Maria Luisa Carcedo, who was named as…
Carlos Espina, managing director of COMSA Cleanroom Technology, a leading Spanish engineering firm, highlights the company’s great successes over the last few years, their international reach, and their strategy to…
Fernando Álvarez, director general of Allergan Iberia, highlights the market’s shift towards more holistic innovation and the company’s main growth drivers, especially in the field of aesthetics. Furthermore, he touches…
Although death rates due to cardiovascular diseases in Spain are among the lowest in the EU, they represent the main cause of death in Spain, accounting for 30% of all…
Kerman Elordi, managing director of Nekicesa, describes the key trends impacting the pharmaceutical and packaging industries, how the company leverages innovation to meet market needs a first mover in technology,…
Fernando Prados Roa, deputy minister of health for Madrid, discusses the health paradigm of the community and elaborates on the role of SERMAS in managing and coordinating the city’s public…
Baltasar Lobato, managing partner of health and life sciences at EY Spain, highlights the major market trends affecting the public and private healthcare sector as well as the pharmaceutical market.…
See our Cookie Privacy Policy Here
